scPharmaceuticals (SCPH) Expected to Announce Quarterly Earnings on Tuesday

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $11.63 million for the quarter.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.05. The business had revenue of $12.15 million during the quarter, compared to analyst estimates of $12.08 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. On average, analysts expect scPharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

scPharmaceuticals Stock Performance

Shares of NASDAQ SCPH traded down $0.09 during trading on Friday, reaching $2.42. 149,928 shares of the company traded hands, compared to its average volume of 358,206. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The firm has a 50 day simple moving average of $2.64 and a 200-day simple moving average of $3.22. scPharmaceuticals has a 52-week low of $1.94 and a 52-week high of $5.65. The stock has a market capitalization of $121.69 million, a PE ratio of -1.27 and a beta of 0.17.

Wall Street Analysts Forecast Growth

SCPH has been the subject of a number of research reports. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday, March 20th. Maxim Group lowered their target price on scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, March 20th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.